[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589091":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":12,"locations":25,"responsibleParty":45,"collaborators":12,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":12,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":12,"studyType":61,"phases":62,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":28,"whyStopped":12,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"College of Physicians and Surgeons Pakistan","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Treatment","NO_INTERVENTION","Standard treatment - Antibiotic such as ampicillin in a dose of 50mg\u002F\u002Fkg\u002Fdose x TDS",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Adjuvant Therapy","EXPERIMENTAL","Standard Treatment along with Melatonin @ 1 mg\u002Fdose in infants and 2.5 to 3mg\u002Fdose in children three times a day for 14 days",[18],"Drug: Melatonin",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DRUG","Melatonin","1 mg\u002Fdose in infants and 2.5 to 3mg\u002Fdose in children three times a day for 14 days",[14],[26],{"facility":27,"status":28,"city":29,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Pakistan Institute of Medical Sciences","RECRUITING","Islamabad","44000","Pakistan","PK",{"type":34,"coordinates":35},"Point",[36,37],73.04329,33.72148,{"lat":37,"lon":36},[40],{"name":41,"role":42,"phone":43,"phoneExt":12,"email":44},"Mian Muhammad hassan Ahmed DR. Hassan, Post Graduate Resident","CONTACT","+92-308-8819982","Hassan965990@gmail.com",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"SPONSOR_INVESTIGATOR","Mian Muhammad Hassan Ahmed","Post Graduate Resident","100589091","phase-1-the-role-of-melatonin-as-an-adjuvant-therapy-in-childhood-pneumonia-100589091",false,"NCT06949904","The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia","Inclusion Criteria:\n\n* 1 month to 12 years\n* Both genders\n* Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition\n\nExclusion Criteria:\n\n* Hospitalized within 14 days prior to the study\n* Known TB exposure\n* Active varicella or herpes simplex infection\n* Allergy to the study medication\n* Currently taking melatonin\n* Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care\n* Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption\n* Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric","ALL","1 Month","12 Years",{"count":59,"type":60},60,"ESTIMATED","INTERVENTIONAL",[63,64],"PHASE1","PHASE2","The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone.\n\nThe hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.\n\nThe control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.",[67],"Pneumonia Childhood",[69,70,22],"Pneumonia","Childhood pneumonia","2025-04-25",{"date":73,"type":74},"2025-04-29","ACTUAL",{"date":76,"type":60},"2025-05",{"date":78,"type":60},"2026-01",{"name":47,"class":6},1]